 It was developed by Johnson & Johnson, in partnership with Recombinant Data Corporation.The platform was released in Jan 2012 and has been governed by the tranSMART Foundation since its initiation in 2013.In May 2017, the tranSMART Foundation merged with the i2b2 Foundation to create an organization with the key mission to advance the field of precision medicine.